Number of pages: 100 | Report Format: PDF | Published date: February 17, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market Size Value in 2021 |
US$ 1.5 billion |
Revenue Forecast in 2030 |
US$ 3 billion |
CAGR |
8.8% |
Base Year For Estimation |
2021 |
Forecast Period |
2022-2030 |
Historical Year |
2020 |
Segments Covered |
Treatment, Disease Management, End-user, and Region |
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global hemophilia B treatment market was valued at US$ 1.5 billion in 2021 and is expected to register a revenue CAGR of 8.8% to reach US$ 3 billion by 2030.
Hemophilia B Treatment Market Fundamentals
Hemophilia B is a rare disease in which the blood does not clot normally due to the lack of blood-clotting proteins (clotting factors). Hemophilia B patients may bleed more profusely and for a longer period. Hemophilia B, in its severe stage, can cause internal bleeding, particularly in the knees, ankles, and elbows. Internal bleeding poses a life-threatening risk and can harm tissues and organs.
Hemophilia B is a coagulation factor deficit caused by low or absent levels of factor IX (FIX). The symptoms of recurrent prolonged bleeding are caused by inadequate or absent plasma FIX levels, which cleave and activate FIX within the coagulation cascade. FIX is a plasma protease that functions in the intrinsic blood coagulation pathway and depends on vitamin K.
Symptoms of hemophilia B vary widely from patient to patient. The severity of hemophilia B can range from mild to severe. Individuals with mild hemophilia have factor IX levels that range between 5% and 40% of normal; those with moderate hemophilia have factor levels that range between 1% and 5% of normal; and those with severe hemophilia have factor levels that fall below 1% of normal.
Individuals suffering from moderate to severe hemophilia undergo spontaneous bleeding into any organ, including the kidneys, stomach, intestines, and brain. Bleeding within the kidneys, stomach, and intestines can result in hematuria, melena, or hematochezia. This bleeding can reach the brain and induce headaches, stiff necks, vomiting, seizures, and mental status abnormalities, such as excessive drowsiness, poor arousal levels, and even death.
[67667577]
Hemophilia B Treatment Market Dynamics
Increasing incidences of hemophilia B is the key factor influencing the global hemophilia B treatment market. A spontaneous mutation brings on about one-third of instances. The U.S. Centers for Disease Control and Prevention (CDC) estimate that 1 in 5,000 live births were expected to result in hemophilia in 2022. In the U.S., there are between 30,000 and 33,000 hemophiliacs. Hemophilia B affects four times less common than hemophilia A. The disease is more common in males than in females. According to the National Center of Biotechnology and Information (NCBI) estimates in 2022, hemophilia B affects 1 in 40,000 males, which is almost 15% of all hemophilia cases. All ethnic groups are equally distributed among them. Due to a higher prevalence of consanguineous marriages, certain cultures, such as Egyptians and Ashkenazi Jews, have higher disease incidences.
Increased drug approvals for treating hemophilia B are fueling revenue growth in the global hemophilia B treatment market. For instance, in November 2022, the Food and Drug Administration (FDA) approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy. The drug is indicated for treating people with Hemophilia B, receiving Factor IX prophylactic medication, having a current or previous life-threatening hemorrhage, or having repeated, major spontaneous bleeding episodes. Similarly, Shanghai Vitalgen BioPharma Co. Ltd. is researching to evaluate the safety and efficacy of VGB-R04 in adult hemophilia B patients.
The growth of the global hemophilia B treatment market is likely to be constrained due to poor healthcare standards and fewer treatment alternatives in low-income regions, such as the Middle East and Africa.
Hemophilia B Treatment Market Ecosystem
The global hemophilia B treatment market has been analyzed from four perspectives: treatment, disease management, end-user, and region.
Hemophilia B Treatment Market by Disease Management
[85675556]
Based on disease management, the global hemophilia B treatment market has been segmented into recombinant factor IX therapy, gene therapy, and others.
The recombinant factor IX therapy segment leads the global hemophilia B treatment market. Recombinant DNA technology is used to create recombinant IX factors. It has structural and functional traits with endogenous factor IX. It shares the main amino acid sequence with the Ala148 allelic variant of human factor IX. This is in contrast to the human Factor IX complex, which is developed from human blood. Recombinant Factor IX is recommended for adult and pediatric patients to manage and avoid bleeding.
The gene therapy segment is expected to show high revenue growth during the forecast period. Gene therapy has the potential to heal hemophilia B patients by creating continuous endogenous production of factor IX (FIX) after the transfer of a functioning gene to replace the faulty gene.
Hemophilia B Treatment Market by Treatment
Based on treatment type, the global hemophilia B treatment market is segmented into on-demand and prophylaxis.
The most common treatment for hemophilia B is on-demand treatment. This involves treating bleeding as it occurs, using either factor IX concentrate or factor IX complex. Factor IX concentrate is a purified form of factor IX. In contrast, the factor IX complex is a mixture of factor IX and factor X, both needed for a normal blood clot. Prophylaxis treatment involves regularly infusing factor IX to prevent bleeding episodes from occurring. Both treatment options have their advantages and disadvantages. The best option for each individual depends on several factors, including the severity of the condition, the frequency of bleeding episodes, and the individual's personal preferences.
Hemophilia B Treatment Market by End-user
Based on end-user, the global hemophilia b treatment market is segmented into hospitals, specialty clinics, and home care.
The hospital segment dominates the global hemophilia B treatment market owing to the increased patient footfall in hospitals due to access to a multidisciplinary team of healthcare providers. In addition, hospitals typically have the necessary resources and equipment to treat hemophilia B, such as on-site infusion centers and specialized clinics. This can be especially beneficial for patients requiring frequent infusions or other treatments, as it can save their time and avoid the inconvenience of traveling to multiple locations for care.
Hemophilia B Treatment Market by Region
Regionally, the global hemophilia B treatment market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America accounted for the majority of revenue share in 2021, attributed to the rising awareness about the condition, improved diagnosis and treatment, and the availability of new therapies. Additionally, the rising number of hemophilia B cases in the region has also increased the number of patients seeking treatment, leading to further revenue growth in the market. Furthermore, the availability of cost-effective treatments and the increasing number of collaborations between pharmaceutical companies and research institutions are also driving the North America hemophilia B treatment market.
The market in Asia Pacific is anticipated to expand with a high revenue CAGR during the forecast years. Leading players are focusing on the launch of many new pipeline drugs for hemophilia B. In addition to the launch of new drugs, increased diagnosis activities are also influencing the hemophilia B treatment market in the region. Moreover, the rising focus of players, such as Sun Pharma, Baxalta, and Novo Nordisk, to spread awareness of hemophilia B is fueling revenue growth in the region.
Hemophilia B Treatment Market Competitive Landscape
The prominent players operating in the global hemophilia B treatment market are:
The high prevalence of hemophilia B, the increase in approval of new therapies for the treatment, and the rise in diagnosis practices are driving market revenue growth.
Aspen Holdings, Baxter, EMERGENT, Mylan N.V., and Bristol Myers Squibb Company are the top market players.
The high cost of treatments, such as gene therapy, can restrain the global hemophilia B treatment market revenue growth. Also, due to low healthcare standards, diagnosis practices and treatment activities are limited in low-income countries, such as the Middle East and Africa.
The global hemophilia B treatment market is expected to register growth at a revenue CAGR of 8.8% during the forecast period from 2022 to 2030.
The recombinant factor IX therapy segment occupies the largest revenue share in the global hemophilia B treatment market.
*Insights on financial performance are subject to the availability of information in the public domain